Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study

NCT02029378 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gullian Barre Syndrome

Interventions

DRUG: Eculizumab

Sponsor

NHS Greater Glasgow and Clyde

Collaborators

[object Object]